PHARMACY RESIDENT
PRACTICE-BASED RESEARCH GRANT:
Practice Advancement Initiative (PAI)

Application Instructions and Guidelines

PROGRAM TIMELINE AT-A-GLANCE:
• Application Open: August 1, 2018
• Deadline: November 1, 2018
• Grantees Announced: January 2019

Administered by the ASHP Foundation

©Copyright 2018 ASHP
Foundation All
rights reserved
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant Program Description</td>
<td>3</td>
</tr>
<tr>
<td>Eligibility</td>
<td>3</td>
</tr>
<tr>
<td>Funding Information</td>
<td>5</td>
</tr>
<tr>
<td>Grant Recipient Responsibilities</td>
<td>5</td>
</tr>
<tr>
<td>Grant Selection Criteria</td>
<td>7</td>
</tr>
<tr>
<td>Itemized Instructions for Grant Application</td>
<td>9</td>
</tr>
</tbody>
</table>
Grant Program Description

The ASHP Foundation is offering a research grant program to support practice-based research, related to the ASHP/ASHP Foundation Practice Advancement (PAI), conducted by residents in ASHP-accredited pharmacy residency programs or by residents in pharmacy residency programs that have submitted an application for ASHP accreditation. A secondary goal of the program is to develop pharmacy residents’ research skills while fostering development of mentoring relationships with more experienced senior investigators.

The proposed practice-based research must be aligned with:

- The vision, mission and strategic priorities of the ASHP Foundation;
- The set of assumptions, beliefs and recommendations for advancing pharmacy practice from the 2010 and 2014 ASHP/ASHP Foundation Pharmacy Practice Model Initiative Summits.

Submission of studies that evaluate advancing pharmacy practice in hospitals, health systems, and other ambulatory settings is invited. Practice-based research affects a wide range of practice model topics; including the utilization of technology, role delineation changes for the pharmacists and non-pharmacists, or enhancing patient care opportunities for pharmacists.

Clinical studies, including pharmacokinetics research and medication effectiveness studies are not supported through this program.

ASHP Foundation

As the philanthropic arm of ASHP, our mission is to improve the health and well-being of patients in health systems through appropriate, safe and effective medication use. ASHP represents pharmacists who serve as patient care providers in acute and ambulatory settings. The organization’s more than 45,000 members include pharmacists, student pharmacists and pharmacy technicians. For over 75 years, ASHP has been on the forefront of efforts to improve medication use and enhance patient safety.

The ASHP Foundation pursues its mission through provision of awards, research grants, and leadership development programs. The ASHP Foundation has a long track record of administering research grants and practitioner recognition programs that use stringent external review processes to select program recipients and participants. Visit our website to learn more about the ASHP Foundation.

Eligibility

The proposed research must focus on the advancement of pharmacy practice and be conducted by a pharmacy resident in an ASHP-accredited residency program or a program that has applied for ASHP residency accreditation.

- The principal investigator must be a new practitioner pharmacist within five (5) years of completion of their pharmacy degree. New practitioner pharmacists who are current residents in an ASHP-accredited pharmacy residency program (i.e., PGY1, PGY2, or combined residency/Master’s program) are eligible for this grant.
- The principal investigator must be a licensed pharmacist.
• The principal investigator must be an ASHP member.

• A senior investigator must participate on the research team as a mentor/advisor.
  
  o In the application process and grant progress reports, evidence must be included regarding the support and involvement of the senior investigator.
  
  o For this grant program, the senior investigator assumes responsibility for compliance with all requirements of the grant program.
  
  o The senior investigator does not have to be a pharmacist.
  
  o Applicants are strongly encouraged to include an individual with a strong research track record as the senior investigator. History of publication of original research in peer-reviewed biomedical journals and receipt of extramural grant funding will be used to evaluate the senior investigator’s research track record.
  
  o Senior investigators cannot apply for more than one grant in an application cycle.

• The study timeline should not exceed 18 months from project initiation.

• Consideration should be given to allocating a portion of the budget to support biostatistics consultation.

• The proposed research must be submitted to an institutional review board (IRB) for approval. Evidence of IRB approval must be provided to the ASHP Foundation upon acceptance of the grant award. Grant funds will not be disbursed until evidence of IRB approval, or exemption from review, has been received.

• Individuals who previously served as a principal investigator on any ASHP Foundation grant are eligible to apply if all work, including journal submission of the study findings, on the previously funded research is complete. If a tie score occurs during the grant review process, the grant will be awarded to the applicant(s) who has/have not received a grant from the ASHP Foundation previously.

• Not-for-profit organizations, for-profit entities, and government agencies are eligible to apply to this program. If a for-profit entity or government agency is a grant recipient, the monetary award provided by the ASHP Foundation must be received and managed by a 501(c)3 not-for-profit organization. Applicant organizations must be in the United States of America to be eligible for the grant.

• **Not Eligible:**
  
  • Clinical Studies, including pharmacokinetic studies and medication effectiveness studies are not supported through this program.

  • Members of the ASHP and ASHP Foundation boards of directors as well as ASHP and ASHP Foundation staff are not eligible to serve as a member of the investigator team for this research grant program.

• The research must comply with the [NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research](https://www.nih.gov/health-information-research/cr-funding/inclusion-guidelines) that was amended in October 2001.

• The research must comply with the [NIH Policy and Guidelines On the Inclusion of Children As Participants in Research Involving Human Subjects](https://www.nih.gov/health-information-research/cr-funding/inclusion-guidelines).

• Principal and Senior Investigators cannot apply for more than one grant in an application cycle.
**Funding Information**

Up to eight (8) $5,000 grants will be awarded. Grants will be awarded to pharmacy residents to provide funding for specific practice-based research related to advancing pharmacy practice models and are not intended for long-term support of research programs. Facilities and administrative cost rates that do not exceed 8% of the total requested budget is allowed. Grants will be awarded to individuals and the funds will be disbursed directly to the sponsoring institution for administration.

**Funds may not be applied to:**
- Resident salaries and/or benefits;
- Ongoing general operating expenses and/or existing deficits;
- Purchase of permanent equipment, facilities, or software, or other capital costs;
- Endowment contributions; and
- Stipends or loans.

**Funding is generally available for:**
- Salary support for study personnel including biostatisticians;
- Institutional review board fees;
- Consumable supplies and services;
- Travel essential to the conduct of the proposed project;
- Patient expenses/reimbursement;
- Travel to present project findings in the range of $1,000 to $1,500 per project. Travel exceeding this range may be submitted for approval following completion of study to over additional presentation opportunities that enhance dissemination of results; and
- Facilities and administrative cost rates that do not exceed 8% of the total direct costs.

**Grant Recipient Responsibilities**

- The grant period of activity will begin upon notice of grant award by the ASHP Foundation and will expire 18 months after the initial notification.
- Following initial disbursement of funds, the grantees must submit Quarterly Research Reports to the ASHP Foundation that address:
  - Progress toward completion of activities included on the study timeline for the quarter in question;
  - Any protocol modifications and documentation of IRB review and approval of such modifications; and
  - A summary of all adverse events associated with execution of the study during the quarter in question and documentation of IRB review of such adverse events.
- Within 60 days of study completion, the grantees must submit a Final Research Report to the ASHP Foundation. This report will be submitted via a survey and must include:
• A summary of the study results including statistical analysis, if applicable;
• Preliminary conclusions;
• A summary of all adverse events associated with execution of the study and documentation of IRB review of such adverse events;
• A summary of all protocol modifications and documentation of IRB review and approval of such modifications;
• Lessons learned, including barriers and facilitators;
• Implementation recommendations; and
• Specific plans for presentation and publication of the study findings.

• Within 60 days of submission of the Final Research Report, the grantees must submit a system-generated Final Financial Report. This report must include a complete and full accounting of the expenditure of ASHP Foundation funds related to the execution of the study.

• Any unused funds must be returned to the ASHP Foundation by the grantees within 120 days of submission of the Final Financial Report.

• If, for any reason, the grantees do not complete the project, the senior investigator must inform the ASHP Foundation in writing within 30 days of study termination. Within 60 days of study termination, the grantees are required to complete the Final Research Report and a system-generated Final Financial Report and return any unused funds to the ASHP Foundation as described above.

• The grantee may request one grant extension. Only one extension will be granted for any study. The project must be completed and all other requirements of the grant fulfilled by the end of the extension period.

• If the findings of the above named study are presented at a national pharmacy meeting, ASHP retains the right of first refusal for presentation of the study and its findings at an ASHP meeting.

• The ASHP Foundation requires submission of study results to a peer-reviewed scientific journal within 6 months of study completion. If the study results are submitted to a pharmacy journal, the American Journal of Health-System Pharmacy retains the right of first refusal for publication.

• The principal investigator will notify the ASHP Foundation when articles containing the study findings are published.

• All presentations, publications, and other communications regarding this study must include the following acknowledgement: “This study was funded (or partially funded) by a research grant from the ASHP Research and Education Foundation.”

• By accepting this award, the grantee agrees to undertake all reasonable efforts to complete the study and take responsibility for fulfilling the terms described within the award letter.

• The recipient institution is responsible for the actions of its employees and other research collaborators, including third parties, involved in the proposed research. The recipient institution will inquire into and, if necessary, investigate and resolve promptly and fairly all instances of alleged or apparent research misconduct related to this ASHP Foundation-sponsored research in accordance with federal regulations on research misconduct (see 42 CFR part 93, “Public Health Service Policies on Research Misconduct.”) and the U.S. Department of Health and Human Services Grants Policy Statement (see
The recipient institution must report promptly to the ASHP Foundation any incident of alleged or apparent research misconduct involving ASHP Foundation-sponsored research that it judges as warranting investigation and must advise the ASHP Foundation of any decision to initiate an investigation. The recipient institution must also notify the ASHP Foundation if it intends to close a case at the inquiry or investigation stage based on an admission of responsibility, settlement, or for any other reason.

If a misconduct investigation has been initiated, the recipient institution must take any necessary steps, in addition to its normal and ongoing responsibilities under the grant, to protect human subjects, protect the scientific integrity of the project, provide reports to the ASHP Foundation, and ensure the proper expenditure of funds and continuation of the project during the investigation, if appropriate.

If the recipient finds research misconduct by anyone working on ASHP Foundation-supported research, whether at its organization or at a third-party organization, the recipient institution must assess the effect of that finding on the ability to continue that project, as originally approved, and must promptly request ASHP Foundation prior approval of any intended change of PI or other key personnel. In addition, the ASHP Foundation may withdraw approval of the principal investigator or other key personnel, disallow costs associated with the invalid or unreliable research, suspend or terminate, in whole or in part, the grant award.

Grant Selection Criteria

Grant application reviewers will use the following criteria to evaluate applications:

Specific Aims and Hypothesis (20 points maximum):
Are the study objectives consistent with the specific grant program focus and the strategic priorities of the ASHP Research and Education Foundation? Is the research question clear and well-defined? Are the overall objectives original and innovative? Are the objectives measurable? Is the number of objectives reasonable based on available funding?

Rationale and Significance (10 points maximum):
Do the investigators clearly explain why this study should be undertaken? Does this study address an important problem? Is there an adequate review of the relevant literature included in the proposal? Does the literature review demonstrate that the investigator understands the field and has a balanced and adequate knowledge of it? Do the investigators identify gaps in the existing evidence base and propose how the proposed study will fill those gaps? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? Do the investigators identify the next logical stages of research beyond the current application?

Innovation (10 points maximum):
Is there a justification within the background section about the research field that led to the proposed study? Is the project original and innovative? For example, does the project challenge existing paradigms or clinical practice or address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts,
approaches or methodologies, tools, or technologies for this area? If the study is not innovative but is essential to move the field forward, does the applicant discuss this in the proposal? What will be the effect of this study on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

**Investigators and Environment (15 point maximum):**

Are the principal investigator and other key personnel appropriately trained and well suited to carry out this work? Is the proposed work appropriate to the experience level of the principal investigator and the other members of the research team, including the senior investigator, if applicable? Do the principal investigator and the research team bring complementary and integrated expertise to the project? Is the research team interdisciplinary in its composition? Is a biostatistician included on the research team? Is there evidence of a commitment to collaboration within the research team? Does the scientific environment in which the work will be done contribute to the probability of success? Does the proposed study benefit from unique features of the scientific environment, or subject population, or employ useful collaborative arrangements? Is there evidence of institutional support?

**Approach (40 points maximum):**

Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well-integrated, well-reasoned, and appropriate to the aims of the project? Do the investigators propose clear and detailed study methods? Will the methods enable the researcher to address the stated objectives and hypothesis? Do the procedures to be followed include, when applicable: appropriate study design; sampling techniques and a description of the population from which the sample will be recruited; controls; procedures for collection, storage and quality control of data for the major outcome variable, secondary outcomes, and other covariates; assurance of availability of subjects and/or facilities to be used; feasibility of plans for recruitment and retention of subjects; and plans for data analysis including biostatistics support? Are methods problems anticipated and alternative approaches proposed? Can the proposed study methods be replicated and generalized?

**Scope and Timeline (5 points maximum):**

Do the investigators justify that the proposed timeline is realistic? Is there evidence the study can be completed in the proposed time period? Do the investigators present information to support the feasibility of the study (e.g., pilot data)? Will sufficient patients/subjects be available for completion of the project within the proposed time period?

**Additional Review Considerations**

In the written review and during the review call, reviewers should also address protection of human subjects, inclusiveness, patient privacy and safety protections, and budget/budget justification.

**Protection of Human Subjects from Research Risk:** Do the investigators adequately address human subjects’ protections?

**Inclusiveness:** Does the research plan address gender, racial and ethnic minority balance?

**Privacy and Security Protections for Patients:** Do the investigators adequately address patient privacy and safety issues?
**Overall Funding Priority Score = 1-9**

Using the following rating scale, reviewers will provide an overall priority score to reflect their overall assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved. This score represents the reviewers overall assessment of the application and is not based only on the criteria-based score described below.

<table>
<thead>
<tr>
<th>Impact</th>
<th>Score</th>
<th>Descriptor</th>
<th>Additional Guidance on Strengths/Weaknesses</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>1</td>
<td>Exceptional</td>
<td>Exceptionally strong with no weaknesses</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Outstanding</td>
<td>Outstanding</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Excellent</td>
<td>Very strong with only some minor weaknesses</td>
</tr>
<tr>
<td>Medium</td>
<td>4</td>
<td>Very Good</td>
<td>Strong but with numerous minor weaknesses</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Good</td>
<td>Strong but with at least one moderate weakness</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Satisfactory</td>
<td>Some strengths but also some moderate weaknesses</td>
</tr>
<tr>
<td>Low</td>
<td>7</td>
<td>Fair</td>
<td>Some strengths but with at least one major weakness</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>Marginal</td>
<td>A few strengths and a few major weaknesses</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Poor</td>
<td>Very few strengths and numerous major weaknesses</td>
</tr>
</tbody>
</table>

**Minor Weakness:** An easily addressable weakness that does not substantially lessen impact. **Moderate Weakness:** A weakness that lessens impact. **Major Weakness:** A weakness that severely limits impact.

---

**Itemized Instructions for Online Grant Application**

**Project**

- Study Title: The study must relate directly to advancing pharmacy practice models in hospitals, health systems, or other ambulatory settings.
- Project Period: Funds may be requested for a maximum period of 18 months.
- Total Budget Requested: Total amount requested cannot exceed $5,000 for an 18-month period. The total budget, direct costs and facilities/administrative costs, cannot exceed $5,000.
- Is this study focused on Practice Advancement (PAI)? If answered "no" to the question above, please contact foundation@ashp.org to be directed to the correct application.

**Pharmacy Resident Investigator**

- **Note:** The pharmacy resident must be participating in an ASHP-accredited residency program or a program that has applied for ASHP accreditation.
• ASHP Member ID (active ID required)
• Credentials (Degrees(s)
• Current Position title, as well as department or division in which pharmacy resident is currently employed.
• Physical mailing address of place of employment, including department.
• Business telephone number at place of employment.
• Email address that is most commonly used for frequent communication.
• Percentage Effort Committed to Study: Percent effort is the total percentage of the investigator’s time that he/she will commit to this study. For example, if an investigator works 50 hours per week and expects to commit 5 hours per week to the study, his/her percent effort would be 10%.
• Affirm that the principal investigator is a PGY1 or PGY2 pharmacy resident.
• Does your residency program combine residency with a master’s degree?

Senior Investigator

• The senior investigator does not have to be a pharmacist. The senior investigator must have the requisite research skills and experiences to supervise the resident’s research activities. Applicants are strongly encouraged to identify individuals with a history of publishing original research in peer-reviewed biomedical journals and receipt of extramural grant support as the senior investigator. The individual named as senior investigator must assume primary responsibility for the study and serve as the senior investigator for the entire grant period.
• Please note: Members of the ASHP and ASHP Foundation Board of Directors, as well as ASHP and ASHP Foundation staff are not eligible to serve as a member of the investigator team for this research grant program.
• ASHP Member ID, if applicable.
• Degree(s)
• Current Position title
• Institution/Organization name.
• Physical mailing address at place of employment.
• Business telephone number at place of employment.
• Email address that is most commonly used for frequent communication.
• Percentage Effort Committed to Study: Percent effort is the total percentage of the investigator’s time that he/she will commit to this study. For example, if an investigator works 50 hours per week and expects to commit 5 hours per week to the study, his/her percent effort would be 10%.

Sponsoring Institution and Grant Officer

• Not-for-profit organizations, for-profit entities, and government agencies are eligible to apply to this program. If a for-profit entity or government agency is a grant recipient, the monetary award provided by the ASHP Foundation must be received and managed by a 501(c)3 not-for-profit organization. The institution must be in the
United States of America to be eligible for the grant.

- The sponsoring institution is that location at which the research will be conducted. Grant checks will be made payable to the institution name listed.
- Is the sponsoring Institution a tax-exempt entity
- Institution/Organization Name
- Grant Officer Name: List the grant officer at the sponsoring institution who will be responsible for monitoring of grant fund use. For institutions that do not have internal grants management divisions, the institution must identify an appropriate entity (e.g., related healthcare foundation) to receive the funds and monitor their use.
- Grant Officer Title: Title of the grant officer must directly reflect an appropriate individual to receive the funds and monitor their use.
- Physical mailing address of the grant officer that all grant correspondence will be sent to.
- Business telephone number of grant officer.
- Email address that is most commonly used for frequent communication.

Other Investigators
- All other professionals engaged in project for whom salary support is NOT being requested must be named here with his/her credentials, institution name and department/division, email address, and his/her percent effort dedicated to this study. If institutional in-kind contribution of time for these members of the investigator team will be required for completion of the proposed research, a support letter that confirms this institutional support should be included. (*Do not include the pharmacy resident and senior investigator here.*)
- Provide: Full Name, Title & Credentials, Institution Name, Dept./Division, Email Address, and Percent Effort.

Detailed Budget
(a) PERSONNEL
All personnel for whom salary support is requested must be named in this section. Salary support is available only for study personnel (e.g., technical personnel; clerical personnel; and other professional personnel.) Resident salaries and fringe benefits are not allowed under this grant program. Strong consideration should be given to allocating a portion of the budget to support biostatistics consultation. In the personnel budget justification section, provide a detailed justification that describes each individual’s role. The budget justification should correspond directly to the project plan.

(b) CONSUMABLE SUPPLIES
All consumable supplies must be itemized as to description, number, cost per unit, and total cost. If exact costs are not known, estimates must be provided. Provide a detailed justification for each budget item. The budget justification should correspond directly to the project plan.

(c) TRAVEL
Only travel costs essential to the conduct of the project are eligible for funding. Travel to present project findings is acceptable in the range of $1,000 to $1,500 per project. In the travel budget justification, provide a detailed justification for each budget item. All
travel to present study findings should be supported through grant or institutional funds. Estimated costs for meeting registration fees, airfare, lodging, meals, and ground transportation must be provided.

(d) OTHER EXPENSES
All other expenses not already specified must be itemized and justified in relation to the project. Permanent equipment, facility construction or renovation, and software are not eligible for funding. Provide a detailed justification for each budget item. The budget justification should correspond directly to the project plan.

(e) IN KIND SERVICES
Provide any detail necessary to describe the extent of the in-kind services provided

(f) FACILITIES AND ADMINISTRATIVE COSTS
Requests for support for facilities and administrative costs rates cannot exceed 8% of the direct costs.

GRAND TOTAL budget should be the same as Item I (d).

Supporting Documents Required
(a) UPLOADS
Each of the following nine headings must appear in the stipulated order:

Research Plan
Components
Description of proposed research plan on no more than ten (10) pages (using 11 point font or larger, 8.5 x 11 inches paper, 1-inch margins, single spacing and single-sided pages) with numbered pages under the following headings:

1. Abstract of proposal (limit to one page with a focus on objectives and methods)
2. Specific Aims and Hypothesis
3. Rationale and Significance
4. Innovation
5. Investigators and Environment
6. Approach
   Detailed study procedures;
   Power calculation, if applicable;
   Plans for data analysis; and
   Procedures for recruitment, retention, and protection of subjects, if applicable
7. Human Subjects/Inclusiveness/Privacy
8. Scope and Timeline
9. References

Including the abstract and references, the narrative of the project plan may not exceed ten (10) pages (using 11 point font or larger, 8.5 x 11 inch paper, 1 inch margins, single spacing and single sided pages). Applicants should strictly comply with font size, paper size, spacing and page limit requirements.
(b) BIOGRAPHICAL DATA
The biographical sketch should list all of the applicants’ peer reviewed publications and should be submitted in the format acceptable by the NIH and AHRQ, links included below.

<table>
<thead>
<tr>
<th>Biographical Sketch Format Page (non-fellowship)</th>
<th>Date Posted</th>
<th>Blank Format Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9/2017</td>
<td>MS Word</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• <a href="https://grants.nih.gov/grants/forms/biosketch.htm">https://grants.nih.gov/grants/forms/biosketch.htm</a></td>
</tr>
</tbody>
</table>

(a) CERTIFICATION AND ACCEPTANCE

- This "certification" must be signed by the pharmacy resident investigator, the senior investigator, resident program director or director of pharmacy, and the grant officer.